Serum CD14 and CD88 Mointoring in ICU

Completed

• Conditions: Sepsis

• Registration Number: NCT02120534
• Lead Sponsor: Tanta University

Brief Summary

The present study will be conducted to determine the dynamic changes of serum soluble CD14 and the corresponding changes of serum CD88 and their correlation in critically ill sepsis and SIRS patients.

Detailed Description

A total of ninty four will be included in the study. Forty seven patients are critically ill with evidence of sepsis during ICU stay (sepsis group) and forty seven patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of CD 14 and CD88 will be monitored.

Study Timeline

• Study Start: 2013-03
• Primary Completion: 2014-04
• Study First Submitted: 2014-04-18
• Study First Submitted QC: 2014-04-18
• Study First Posted: 2014-04-22
• Study Completion: 2014-10
• Status Verified: 2014-12
• Last Update Submitted: 2014-12-14
• Last Update Posted: 2014-12-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• The patients staying in ICU for more than 24 hours will be included in the study.

Exclusion Criteria

• Patients received anti-inflammatory drugs or corticosteroids before admission, patients had immunosuppressive illness, patients had chronic organ failure; patients received massive blood transfusion; patients with radiation therapy and patients with previous organ transplantation will be excluded from the study.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
A serum soluble CD14	one week	At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of CD 14 will be monitored.

Secondary Outcome Measures

Name	Time	Method
Survival of ICU patients	Two weeks	Correlation of of serum soluble CD14 and the corresponding changes of serum CD88 and their correlation in critically ill sepsis and SIRS patients and survival.

Trial Locations

Locations (1)

Tanta University Hospitals; 🇪🇬 Tanta, Algharbyia, Egypt